Stories
Aurobindo Pharma Soars to 52-Week High on USFDA Approval for Perampanel Tablets
M
Moneycontrol•05-10-2026, 09:28
Aurobindo Pharma Soars to 52-Week High on USFDA Approval for Perampanel Tablets
- •Aurobindo Pharma shares hit a 52-week high of Rs 1,739.95 after receiving final USFDA approval for Perampanel Tablets.
- •The approved Perampanel Tablets are bioequivalent and therapeutically equivalent to Catalyst Pharmaceuticals' Fycompa Tablets.
- •The product will be manufactured at APL Healthcare's Unit-IV and is slated for launch in Q3FY27.
- •Perampanel tablets are indicated for treating partial-onset seizures and primary generalized tonic-clonic seizures in epilepsy patients.
- •Aurobindo Pharma now boasts a total of 599 ANDA approvals from the USFDA, including 574 final approvals.
Key Questions Answered
Aurobindo Pharma shares touched a 52-week high of Rs 1,739.95 after receiving final approval from the USFDA to manufacture and market Perampanel tablets in multiple strengths.
The Perampanel tablets will be manufactured at Unit-IV of APL Healthcare, a wholly-owned subsidiary of the company, and are scheduled for launch in Q3FY27.
Following the latest development, Aurobindo Pharma holds a total of 599 ANDA approvals from the USFDA, which include 574 final approvals and 25 tentative approvals.
